BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Cambodia, Uzbekistan, Kenya, Afghanistan, Mauritania, Switzerland, Sri Lanka, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic, diabetes and anti-obesity, cardiology, urology and nephrology, gastroenterology and liver, anti-fungal, oncology, anti-viral, hepatology, orthopedic, dermatology, and antibiotics. It also provides specialized inject... [
BFBIO — BF Biosciences Limited
Sector: Pharmaceuticals · Pakistan Stock Exchange
⚠ Prices: 6 Nov 2026 — PSX end-of-day close (feed fetched 23:14 PKT) · Fundamentals: public data collected 6 Nov 2026 · Not live prices.Summary — BFBIO
| Measure | Value |
|---|---|
| Price (Rs, 6 Nov — PSX delayed feed) | 130.90 |
| Change, 6 Nov session (delayed) | -1.30% |
| Volume (shares, 6 Nov session) | 23,848 |
| Market capitalisation | Rs 11.56 bn |
| Revenue (TTM) | Rs 9.81 bn |
| Price / Earnings (P/E) | — |
| Price / Book (P/B) | — |
| Dividend yield | 0.00% |
| Return on equity (ROE) | 12.70% |
| Net margin | — |
| Debt / Equity (as reported by source) | — |
| Revenue growth, 3-year | — |
Company Snapshot
| Paid-up Capital | Rs 265.00 mn |
| Authorized Capital | Rs 1,200.00 mn |
| Shares Outstanding | 88.33 mn |
| Free Float | 26.50 mn |
| Free Float % | 30.0 % |
| Face Value | Rs 3.00 |
| Fiscal Year End | June |
| Avg Volume (12M) | 331,912 |
| Book Value / Share | Rs. 62.03 (Upto 2027 1Q) |
| Total Book Value (computed) | Rs 5.48 bn |
Capital data: SCSTRADE company snapshot, collected 6 Nov 2026. Total Book Value is computed on this page as Book Value / Share × Shares Outstanding.
PSX Scorecard — five checks on this stock's own data
VALUE
0/6
FUTURENo forecast data
PAST
5/6
HEALTH
6/6
DIVIDEND
0/6
Strongest: Financial health (6/6). Weakest: Value (0/6).
How this is scored
Scores are computed mechanically from the data on this page, 0–6 per axis, scaled over the checks that could be run — an axis with no data is labelled, never scored zero for missing data. VALUE: upside to the average analyst target (bands from +30% down), P/E and P/B below the sector median, yield above the sector median. FUTURE: S&P consensus forward EPS and revenue growth bands (only where estimates exist). PAST: revenue and EPS growth across the published financial history, latest year profitable, ROE bands. HEALTH: debt/equity bands, positive latest net margin, no loss-making year in the history. DIVIDEND: yield bands, years of recorded DPS, DPS trend, and payout (DPS ÷ EPS) at or under 100%. The full rule table is in the site's data inventory. Scores are a data summary, not a recommendation.
Performance — BFBIO
Day range — 6 Nov 2026 session
Day lowRs 130.25Close Rs 130.90Day highRs 132.10
Day high/low from the official PSX market-summary feed for the 6 Nov 2026 session.
Investment Case — BFBIO
Strengths — from the numbers
- Revenue grew +522.0% across the published history, FY2022–FY2026 (Rs 1,521m → Rs 9,461m).
- Earnings per share grew +47.6% across the published history, FY2022–FY2026 (Rs 4.85 → Rs 7.16).
Risks / watch points — from the numbers
- Net margin has fallen to 6.68% in FY2026, from 20.19% in FY2022.
Recent performance — FY2026
| Revenue | Rs 9,461m (+62.1% vs FY2025) |
| Net income | Rs 632m (+41.4% vs FY2025) |
| EPS | Rs 7.16 (+29.7% vs FY2025) |
| Net margin | 6.68% |
Latest published fiscal year from the financial history below (StockAnalysis figures, collected 6 Nov 2026).
Generated from the figures above — PSX Analysis data summary, not investment advice.
Quotes — BFBIO
| Quote | Value |
|---|---|
| Last price (Rs) | 130.90 |
| Change, 6 Nov session | -1.30% |
| Day open, 6 Nov (Rs) | 132.10 |
| Day high, 6 Nov (Rs) | 132.10 |
| Day low, 6 Nov (Rs) | 130.25 |
| Previous close — LDCP (Rs) | 132.62 |
| Volume (shares, 6 Nov session) | 23,848 |
| Market capitalisation | Rs 11.56 bn |
Day open/high/low and previous close (LDCP) are from the official PSX market-summary feed for the 6 Nov 2026 session, the same feed that supplies the closing price. 1-year figures are computed from the daily-close chart series below.
Technicals — BFBIO
Classic pivot levels — from the 6 Nov session
| Level | Rs |
|---|---|
| Resistance 2 (R2) | 132.93 |
| Resistance 1 (R1) | 131.92 |
| Pivot point (PP) | 131.08 |
| Support 1 (S1) | 130.07 |
| Support 2 (S2) | 129.23 |
Classic pivots from the 6 Nov 2026 session's high (Rs 132.10), low (Rs 130.25) and close (Rs 130.90) in the official PSX feed. The close sits below the pivot point.
Technicals are mechanical calculations on past prices. They describe momentum and recent trading ranges only — not investment advice.
Company — BFBIO
| Company | BF Biosciences Limited |
| Symbol | BFBIO |
| Sector | Pharmaceuticals |
| Market capitalisation | Rs 11.56 bn |
| Revenue (TTM) | Rs 9.81 bn |
Founded 2006 · Employees 852 — as published by StockAnalysis.
Company description: StockAnalysis company profile, collected 6 Nov 2026.
Exchange record: PSX company profile for BFBIO (Pakistan Stock Exchange data portal).
Financials — BFBIO
Revenue (TTM)
Rs 9,813m
Rs 9,813m
Net income (TTM)
Rs 657m
Rs 657m
EPS (TTM)
Rs 7.44
Rs 7.44
Net margin (TTM)
6.70%
6.70%
Dividend yield
0.00%
0.00%
ROE
12.70%
12.70%
| Measure | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue (Rs m) | 1,521 | 1,810 | 3,659 | 5,837 | 9,461 |
| Operating income (Rs m) | 242 | 269 | 710 | 732 | 1,087 |
| Net income (Rs m) | 307 | 149 | 385 | 447 | 632 |
| EPS (Rs) | 4.85 | 2.35 | 6.09 | 5.52 | 7.16 |
| Net margin | 20.19% | 8.24% | 10.53% | 7.66% | 6.68% |
Trailing twelve months (to Sep 30, 2026, not a completed fiscal year): Revenue Rs 9,813m · Net income Rs 657m · EPS Rs 7.44 · Net margin 6.70%.
Source: StockAnalysis financials, collected 6 Nov 2026 — this stock's published history here spans FY2022–FY2026 (5 fiscal years; the source table publishes a maximum of five completed years per stock). A dash means the source did not publish that figure for that year.
Valuation & Fair Value — BFBIO
Fair P/E Value — sector multiple
Rs 91.51
Current price Rs 130.90 · -30.1%
Formula: sector median P/E 12.30× × EPS Rs 7.44 = Rs 91.51. Sector median across 12 Pharmaceuticals peers with a published P/E — the same basis as the median table below. EPS is the trailing-twelve-month (TTM) figure published in the dataset.
Fair P/B Value — sector multiple
Rs 182.37
Current price Rs 130.90 · +39.3%
Formula: sector median P/B 2.94× × book value per share Rs 62.03 = Rs 182.37. Sector median across 11 Pharmaceuticals peers with a published P/B — the same basis as the median table below. Book value per share from the SCSTRADE company snapshot (Upto 2027 1Q), collected 6 Nov 2026.
1 of 2 measures above the current price. Each measure stands on its own stated basis — they are deliberately not blended into a single fair value. Mechanical estimates computed from published data; not investment advice.
| Measure | BFBIO | Sector median |
|---|---|---|
| Dividend yield | 0.00% | 1.50% |
| Return on equity (ROE) | 12.70% | 21.65% |
Sector median across 14 listed peers in our dataset (sector: Pharmaceuticals), computed only from peers where the measure is published; a median is shown only when at least 5 peers have the measure.
Sector — BFBIO
BFBIO ranks #10 by market capitalisation among the 14 listed Pharmaceuticals stocks in our dataset. Full sector tables: Sectors.
FAQ — BFBIO
What is the current BFBIO share price?
BF Biosciences Limited (BFBIO) last traded at Rs 130.90 in the 6 Nov 2026 session, -1.30% on the day. Prices on this page are the PSX end-of-day close from the official delayed feed, not live prices.
Which PSX sector is BFBIO in?
BF Biosciences Limited (BFBIO) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
What are BFBIO's P/E ratio and dividend yield?
BF Biosciences Limited (BFBIO) shows a dividend yield of 0.00% in the public data collected 6 Nov 2026.
Answers are generated from this page's own figures (public data collected 6 Nov 2026; prices are the 6 Nov 2026 PSX end-of-day close, not live).
BF Biosciences Limited (BFBIO) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
Every figure above comes from public listings collected on 6 November 2026 (StockAnalysis and SmartMoney, merged by symbol), with the price, change and volume refreshed on 6 Nov 2026 from the official PSX delayed market feed (end-of-day close, fetched 23:14 PKT) — delayed figures, not live prices. If this stock was absent from that feed, its price is the previous latest close. A dash means the measure was not published for this stock by the sources, not that it is zero. Compare BFBIO with the market's largest shares in the Top 250 screener, browse the whole market in Stocks A–Z, and read the ratios explainer in Learn.
This page is a data summary for education, not a recommendation to buy or sell BFBIO.